Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | CCR5 | P51681 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3241607 | 0.78 | MAOB (0.48) | KCNH2CNR2AOC3SLC6A2SLC6A3 | |
| SCHEMBL9153358 | 0.71 | IDO1 (0.42) | KCNH2AOC3IDO1SLC6A2SLC6A3 | |
| SCHEMBL10803409 | 0.71 | KCNH2 (0.77) | KCNH2CCR5 | |
| SCHEMBL10803397 | 0.71 | KCNH2 (0.77) | KCNH2CCR5 | |
| SCHEMBL2123502 | 0.70 | IDO1 (0.46) | KCNH2AOC3IDO1SLC6A2SLC6A3 | |
| SCHEMBL27645313 | 0.70 | KCNH2 (0.53) | KCNH2AOC3IDO1SLC6A2SLC6A3 | |
| SCHEMBL27545170 | 0.68 | KCNH2 (0.44) | KCNH2IDO1SLC6A2SLC6A3TAAR1 | |
| SCHEMBL453913 | 0.67 | IDO1 (0.48) | IDO1SLC6A2SLC6A3TAAR1HTR2A | |
| SCHEMBL5506050 | 0.67 | IDO1 (0.48) | IDO1SLC6A2SLC6A3TAAR1HTR2A | |
| SCHEMBL9136930 | 0.67 | IDO1 (0.48) | KCNH2AOC3IDO1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353579-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO LTD (CN) | 2021-11-18 | — | — | US | disclosed |
| US-9872846-B2 | High penetration compositions and uses thereof | TECHFIELDS PHARMA CO., LTD. (CN) | 2018-01-23 | — | — | US | disclosed |
| US-20170209585-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO LTD (CN) | 2017-07-27 | — | — | US | disclosed |
| US-20170209404-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | PREMIER RESEARCH INTERNATIONAL, LLC | 2017-07-27 | — | — | US | disclosed |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO., LTD. (CN) | 2009-09-24 | — | — | US | disclosed |
| WO-2005030734-A1 | DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS | ABBOTT LABORATORIES (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209404-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | KCNH2 4441/4885CNR2 820/4885AOC3 3589/4885 |
| US-20210353579-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | KCNH2 4441/4885CNR2 820/4885AOC3 3589/4885 |
| US-20170209585-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | KCNH2 4441/4885CNR2 820/4885AOC3 3589/4885 |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | KCNH2 4441/4885CNR2 820/4885AOC3 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.